Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data
NCT01134939 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 265
Last updated 2015-01-21
Summary
The question that prompted this study is the extent to which results from clinical trials can be translated into everyday practice (external validity). First and foremost are questions about tolerability and the efficacy of an antiretroviral combination treatment with Viramune and other antiretroviral partners. In particular, adverse events will be recorded depending on gender and the therapeutic effect will be monitored via the course of viral load and improvement of the immune system, based on the CD4 cell count.
Conditions
- HIV Infections
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Boehringer Ingelheim · Boehringer Ingelheim
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-05-31
- Primary Completion
- 2013-12-31
- Completion
- 2013-12-31
Countries
- Germany
Study Locations
More Related Trials
-
Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus
NCT00321438 ·Status: TERMINATED
-
Prospective Observational Epidemiologic Study of Maraviroc's Safety
NCT00665561 ·Status: COMPLETED
-
A Study to Evaluate Virologic Response in Participants Newly Diagnosed With HIV-1
NCT04147325 ·Status: COMPLETED
-
Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
NCT00532168 ·Status: COMPLETED ·Phase: PHASE4
-
Women in Dual With Dolutegravir
NCT05735535 ·Status: UNKNOWN ·Phase: PHASE3
-
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
NCT03382834 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany
NCT02342769 ·Status: COMPLETED
-
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
NCT01967940 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection
NCT02733419 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany
NCT02076386 ·Status: COMPLETED
-
Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events
NCT01417949 ·Status: COMPLETED ·Phase: PHASE4
-
Analytical Treatment Interruption in HIV Positive Patients
NCT02590354 ·Status: COMPLETED ·Phase: NA
-
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
NCT05349838 ·Status: COMPLETED ·Phase: PHASE3
-
CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes
NCT00966160 ·Status: COMPLETED ·Phase: PHASE3
-
Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)
NCT00705419 ·Status: COMPLETED
-
Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy
NCT01365065 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years
NCT03405935 ·Status: COMPLETED ·Phase: PHASE3
-
A Long-term Follow-up of the HIV-NAT Cohort
NCT00411983 ·Status: RECRUITING
-
Structured Treatment Interruption for HIV Patients With Virologic Failure
NCT00188851 ·Status: COMPLETED ·Phase: NA
-
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
NCT01818596 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts
NCT01928407 ·Status: COMPLETED ·Phase: PHASE4
-
Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects
NCT00966329 ·Status: COMPLETED ·Phase: PHASE4
-
HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine
NCT00855413 ·Status: TERMINATED ·Phase: PHASE4
-
Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection
NCT03449706 ·Status: RECRUITING
-
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
NCT01440569 ·Status: COMPLETED ·Phase: PHASE3